Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hayes

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
Clinical and Vaccine Immunology : CVI|December 19, 2008
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continentsMark J Boaz, Peter Hayes, Tony Tarragona, et al.
Plos One|September 30, 2010
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaWalter Jaoko, Etienne Karita, Kayitesi Kayitenkore, et al.
Vaccine|April 29, 2008
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East AfricaWalter Jaoko, Frederick N Nakwagala, Omu Anzala, et al.
Annals of Internal Medicine|February 3, 2016
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized TrialLindsey R Baden, Etienne Karita, Gaudensia Mutua, et al.
The New England Journal of Medicine|November 5, 2025
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine CandidateElissa Malkin, Marija Zaric, Mark Kieh, et al.
BMC Immunology|June 28, 2005
Standardization of cytokine flow cytometry assaysHolden T Maecker, Aline Rinfret, Patricia D'Souza, et al.
The Lancet. Microbe|May 19, 2025
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern AfricaChama Chanda, Freddie Kibengo, Michael Mutua, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
Plos One|August 8, 2012
A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adultsMichael C Keefer, Jill Gilmour, Peter Hayes, et al.
Plos One|December 24, 2010
Equivalence of ELISpot assays demonstrated between major HIV network laboratoriesDilbinder K Gill, Yunda Huang, Gail L Levine, et al.
The Journal of Infectious Diseases|January 13, 2017
First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost RegimensJulien Nyombayire, Omu Anzala, Brian Gazzard, et al.
Clinical and Vaccine Immunology : CVI|December 19, 2008
Concordant proficiency in measurement of T-cell immunity in human immunodeficiency virus vaccine clinical trials by peripheral blood mononuclear cell and enzyme-linked immunospot assays in laboratories from three continentsMark J Boaz, Peter Hayes, Tony Tarragona, et al.
Plos One|September 30, 2010
Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in AfricaWalter Jaoko, Etienne Karita, Kayitesi Kayitenkore, et al.
Vaccine|April 29, 2008
Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East AfricaWalter Jaoko, Frederick N Nakwagala, Omu Anzala, et al.
Annals of Internal Medicine|February 3, 2016
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized TrialLindsey R Baden, Etienne Karita, Gaudensia Mutua, et al.
The New England Journal of Medicine|November 5, 2025
Safety and Immunogenicity of an rVSV Lassa Fever Vaccine CandidateElissa Malkin, Marija Zaric, Mark Kieh, et al.
BMC Immunology|June 28, 2005
Standardization of cytokine flow cytometry assaysHolden T Maecker, Aline Rinfret, Patricia D'Souza, et al.
The Lancet. Microbe|May 19, 2025
Safety and broad immunogenicity of HIVconsvX conserved mosaic candidate T-cell vaccines vectored by ChAdOx1 and MVA in HIV-CORE 006: a double-blind, randomised, placebo-controlled phase 1 trial in healthy adults living without HIV-1 in eastern and southern AfricaChama Chanda, Freddie Kibengo, Michael Mutua, et al.
Pageof 13